Correlation Between Acumen Pharmaceuticals and Catalyst Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acumen Pharmaceuticals and Catalyst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acumen Pharmaceuticals and Catalyst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acumen Pharmaceuticals and Catalyst Pharmaceuticals, you can compare the effects of market volatilities on Acumen Pharmaceuticals and Catalyst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acumen Pharmaceuticals with a short position of Catalyst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acumen Pharmaceuticals and Catalyst Pharmaceuticals.

Diversification Opportunities for Acumen Pharmaceuticals and Catalyst Pharmaceuticals

0.36
  Correlation Coefficient

Weak diversification

The 3 months correlation between Acumen and Catalyst is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Acumen Pharmaceuticals and Catalyst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Catalyst Pharmaceuticals and Acumen Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acumen Pharmaceuticals are associated (or correlated) with Catalyst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Catalyst Pharmaceuticals has no effect on the direction of Acumen Pharmaceuticals i.e., Acumen Pharmaceuticals and Catalyst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Acumen Pharmaceuticals and Catalyst Pharmaceuticals

Given the investment horizon of 90 days Acumen Pharmaceuticals is expected to under-perform the Catalyst Pharmaceuticals. In addition to that, Acumen Pharmaceuticals is 1.92 times more volatile than Catalyst Pharmaceuticals. It trades about -0.01 of its total potential returns per unit of risk. Catalyst Pharmaceuticals is currently generating about 0.03 per unit of volatility. If you would invest  1,806  in Catalyst Pharmaceuticals on September 21, 2024 and sell it today you would earn a total of  340.00  from holding Catalyst Pharmaceuticals or generate 18.83% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Acumen Pharmaceuticals  vs.  Catalyst Pharmaceuticals

 Performance 
       Timeline  
Acumen Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acumen Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Catalyst Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Catalyst Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Acumen Pharmaceuticals and Catalyst Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acumen Pharmaceuticals and Catalyst Pharmaceuticals

The main advantage of trading using opposite Acumen Pharmaceuticals and Catalyst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acumen Pharmaceuticals position performs unexpectedly, Catalyst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will offset losses from the drop in Catalyst Pharmaceuticals' long position.
The idea behind Acumen Pharmaceuticals and Catalyst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Transaction History
View history of all your transactions and understand their impact on performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Volatility Analysis
Get historical volatility and risk analysis based on latest market data